Up next

Autoplay

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

0 Views • 07/17/23
Share
Embed
administrator
administrator
Subscribers
0

Dr Kaufman speaks with ecancertv at ASCO 2016 to discuss the results of phase II JAVELIN Merkel 200 trial, in which patients with metastatic Merkl cell carcinoma received avelumab, a PD-L1 checkpoint inhibitor.

Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with Merkel cell polyomavirus, with limited therapeutic options after 1st-line chemotherapy.

Dr Kaufman describes the results of the JAVELIN trial in which, of a cohort of 88, six patients (9.8%) achieved complete responses, 12 (19.7%) had partial responses, and 7 (11.5%) had stable disease (83.3% responses were ongoing).

He also details the ongoing progression free survival data, and offers that additional clinical evaluation of avelumab for is warranted.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay